# Xaira Therapeutics: Research, South San Francisco, United States

> Xaira Therapeutics: Xaira Therapeutics is an integrated biotechnology company founded in 2023 and publicly launched in April 2024.

Source: https://millionrounds.com/startup/xaira-therapeutics (Millionrounds; every figure on the page links to its filing or article)

United States · [Research startup](https://millionrounds.com/companies)

# Xaira Therapeutics

Xaira Therapeutics is an integrated biotechnology company founded in 2023 and publicly launched in April 2024.

Funding reported Last round: Series A

Research South San Francisco, United States

Company summary

- **Founded:** 2023 3 years old
- **Team:** 160 51 to 200 people
- **Funding reported:** $1.0B in dollars
- **Last round:** Series A Apr 2024

How sure we are

- ✓ **Listed** We know it exists and what it does
- 2 **Funding reported** A company dataset reports a raise
- 3 **Observed** A filing or a dated announcement confirms a round

No round for Xaira Therapeutics has been confirmed by a filing or an announcement yet, so nothing here counts toward an investor's record. [How we decide](https://millionrounds.com/methodology)

## About Xaira Therapeutics

Xaira Therapeutics is an integrated biotechnology company founded in 2023 and publicly launched in April 2024.

With $1 billion in seed funding, it is recognized for having the largest launch in AI-driven drug discovery. Headquartered in South San Francisco, California, and with a research presence in Seattle, Xaira focuses on re-engineering drug discovery and development through advanced generative AI. The company's mission is to transform disease treatment by turning drug discovery into an engineering discipline. Xaira develops its own drugs using a proprietary platform that combines expertise in disease biology, drug design, and AI. Its technological capabilities include molecular design for antibody and protein development, a virtual cell model for predicting outcomes, and integrated proteomics for protein analysis. Xaira primarily operates as a B2B entity, focusing on drug discovery while also exploring potential revenue-sharing models for its AI platforms.

## What company datasets say Xaira Therapeutics raised

Funding, as reported

Reported in all **$1.0B** in dollars

Rounds **1**

Last round **Series A**

Last round size **$1.0B**

Last round date **Apr 2024**

Investors listed **13**

Valuation **$2.1B, Mar 2026**

## Founders and team

From Xaira Therapeutics's own website: 9 on the team.

- **Marc Tessier-Lavigne** Chairman & Chief Executive Officer
- **Bo Wang** Chief AI Scientist
- **Ci Chu** Chief Discovery Officer
- **Debbie Law** Chief Scientific Officer
- **Hetu Kamichetty** Chief Technology Officer
- **Julia Tran** Chief People Officer
- **Alex Gorsky** Director
- **Carolyn R. Bertozzi** Director
- **Kaye Foster** Director

Advisers *Anima Anandkumar* *Diane Mathis* *Jeff Jonker* *Regina Barzilay* *Richard Scheller* *Rod MacKinnon* *Sarah Teichmann* *Scientific Advisor*

## On 3 portfolio pages

Investors who name them

- [ARCH Venture Partners](https://millionrounds.com/fund/arch-venture-partners)
- [Breyer Capital](https://millionrounds.com/fund/breyer-capital)
- [Blake Byers](https://millionrounds.com/fund/blake-byers)

Each firm lists Xaira Therapeutics on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.

## The company, in detail

What they build

Known for

data platforms health care rare diseases immune profiling digital health pharmacogenomics biotechnology research pharmaceutical development ai models nobel laureate enterprises smartphone-based monitoring biological understanding ai platforms biotech funding immunology

Built with from their website

Docker Adobe Amazon CloudFront ANS Spectro Atlassian Flow Intel Nios GitHub ELISA

+8 more

Google Workspace CloudFlare Gem Viewport Meta CSS Recolize scikit-learn Alia

- **Sector:** Research
- **Industry code:** NAICS 541714, SIC 2834, 8731
- **Region:** California
- **Revenue:** $20M a year, as listed
- **Full record:** [Every detail in the company directory](https://millionrounds.com/directory/xaira-therapeutics)

## Research in United States

Startups like it

- [**OpenAI** San Francisco · founded 2011 *Raised*](https://millionrounds.com/company/openai)
- [**Retro Biosciences** Redwood City · founded 2021 *Raised*](https://millionrounds.com/company/retro-biosciences)
- [**NewLimit** South San Francisco · founded 2022 *Raised*](https://millionrounds.com/company/newlimit)
- [**Pathos** New York · founded 2022 *Raised*](https://millionrounds.com/company/pathos)
- [**Colossal Biosciences** Dallas · founded 2021 *Raised*](https://millionrounds.com/company/colossal-biosciences)
- [**Oratomic** South Pasadena *Raised*](https://millionrounds.com/company/oratomic)
- [**Beeline Medicines** Stamford · founded 2025 *Raised*](https://millionrounds.com/company/beeline-medicines)
- [**Element Biosciences** San Diego · founded 2017 *Raised*](https://millionrounds.com/company/element-biosciences)

## Is this your company?

Add your raise, your deck and your story, and put Xaira Therapeutics in front of investors. Or tell us what we have wrong.

[List your startup](https://millionrounds.com/list-your-startup)[Send a correction](https://millionrounds.com/corrections)